Clinical TrialsSearch results
Number of results: 2722
Recruiting
- "Real world treatment practice, effectiveness, and safety of nivolumab combination with chemotherapy as a neoadjuvant therapy for resectable NSCLC patients in Japan, an observational study"
- Resectable Non-Small Cell Lung Cancer
- Matsumoto Hiroki
- 2024-05-07
Recruiting
- [M14-682] Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves through the Body of Pediatric and Adolescent Participants with Active Systemic Juvenile Idiopathic Arthritis.
- Juvenile Idiopathic Arthritis
- Hayato Yamazaki
- 2023-10-16
Recruiting
- [M15-340]A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
- Polyarticular Course Juvenile Idiopathic Arthritis
- Yamazaki Hayato
- 2023-01-18
Other
- [M16-077] A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
- Acute Traumatic Cervical Spinal Cord Injury
- Otani Tetsuya
- 2021-04-02
Not yet recruiting
- [M23-703] A Study to Assess Adverse Events and Change in Disease Activity from Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants with Active Ulcerative Colitis
- Ulcerative Colitis
- Otani Tetsuya
- 2024-05-07
Recruiting
- [M24-122] A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors
- Solid Tumors
- Yamagishi Chika
- 2024-03-15
Other
- [M24-147] Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Hepatocellular Carcinoma
- Yamagishi Chika
- 2023-06-16
Recruiting
- [M24-311]Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
- unresectable metastatic colorectal cancer
- Yamagishi Chika
- 2023-11-10
Recruiting
- [M24-427]ABBV-400 in Select Advanced Solid Tumor Indications
- HCC, PDAC, BTC, ESCC, BC, HNSCC
- Yamagishi Chika
- 2023-12-25